Phosphocreatine (Neoton)

An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996)

Also Known As:

Networked: 1567 relevant articles (62 outcomes, 95 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Delivoria-Papadopoulos, Maria: 30 articles (08/2012 - 01/2002)
2.	Mishra, Om P: 21 articles (08/2010 - 01/2002)
3.	Ashraf, Qazi M: 15 articles (03/2011 - 01/2002)
4.	Mishra, O P: 14 articles (09/2006 - 01/2000)
5.	Delivoria-Papadopoulos, M: 12 articles (09/2006 - 01/2000)
6.	Ashraf, Q M: 9 articles (09/2006 - 01/2001)
7.	Neubauer, Stefan: 8 articles (12/2012 - 09/2002)
8.	Mishra, Om Prakash: 8 articles (03/2011 - 01/2002)
9.	Clarke, Kieran: 7 articles (05/2014 - 05/2005)
10.	Zubrow, Alan B: 7 articles (05/2007 - 01/2002)

Related Diseases

1.	Ischemia 08/05/1996 - "In all subjects during the first 30 s of ischemia inorganic phosphate showed a marked decrease from the value measured at the end of exercise, whilst phosphocreatine maintained the same value reached at the end of exercise. " 04/01/2009 - "Recovery level of phosphocreatine after ischemia was significantly greater when superfused with artificial cerebrospinal fluid (ACSF) with 2 mM EP than when superfused with ACSF without EP. " 02/01/1992 - "[Myocardium-protective effects of phosphocreatine in experimental ischemia-reperfusion]." 06/01/1993 - "[The effect of adaptation to repeated stresses on the recovery of cardiac function and creatine phosphate after total ischemia (a 31P-NMR study)]." 01/01/1992 - "Experiments were conducted on a model of an isolated functioning rat heart to study myocardial protection by normothermic cardioplegic reperfusion (NCR) with phosphocreatine (PC) in 30-minute total ischemia at 37 degrees C. "
2.	Anoxia (Hypoxia) 01/01/1994 - "The observed inhibition of phosphocreatine as well as that of intracellular pH changes after training during hypoxia and quicker recovery of phosphocreatine in submaximal exercise tests, may indicate improved oxidative capacity (i.e. " 08/01/2005 - "In control studies, pH and phosphocreatine fell and P(i) rose during anoxia and recovered within <10 min after reperfusion began. " 01/29/2015 - "CKB is released into the extracellular space by metastatic cells encountering hepatic hypoxia and catalyzes production of phosphocreatine, which is imported through the SLC6A8 transporter and used to generate ATP—fueling metastatic survival. " 10/01/2008 - "Hypoxia exposure in goldfish was characterized by a strong activation of creatine phosphate hydrolysis and glycolysis in liver and muscle. " 08/01/2008 - "Supra- and sub-baseline phosphocreatine recovery in developing brain after transient hypoxia-ischaemia: relation to baseline energetics, insult severity and outcome."
3.	Hypothermia 06/01/2004 - "In addition, hypothermia resulted in a trend toward creatine phosphate preservation in the nonischemic area. " 08/01/1994 - "Increased myocardial contents of creatine phosphate and water were found during both hypothermia and rewarming. " 02/01/1991 - "However, recent studies with creatine phosphate in St. Thomas' Hospital solution demonstrated that additional myocardial protection during hypothermia resulted principally from its calcium-lowering effect in the solution. " 05/01/1990 - "The addition of creatine phosphate in a conservation of 10 mM/l to the solution or donor pretreatment with 70 mg/kg vitamin E was found to potentiate the protective properties of the solution under deep hypothermia. " 12/01/1989 - "During hypothermia, the brain pHi was 0.09 U higher, the phosphocreatine-to-inorganic phosphate (PCR/Pi) ratio 49% larger, and Pi-to-ATP 20% lower than at normothermia. "
4.	Heart Failure 04/01/1994 - "[The efficacy of creatine phosphate in the treatment of patients with heart failure. " 09/01/1996 - "Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo." 11/01/1996 - "With 31P-NMR spectroscopy, we monitored phosphocreatine (PCr) decay and recovery in eight normal volunteers and four heart failure patients performing ischemic plantar flexion. " 01/01/1996 - "It is recommended to include neoton in the scheme of chronic cardiac failure treatment in the dose 3.0 g/day for 10 days." 08/01/1995 - "At 200 g twitch tension, phosphocreatine and pH were found to be significantly lower in the non-trained severe heart failure group compared with the other groups. "
5.	Neoplasms (Cancer) 01/01/2011 - " the effect of phosphocreatine in childhood cancer patients with anthracycline-induced cardiotoxicity, only one RCT is available. " 06/01/2004 - "Phosphocreatine is often diminished in neoplasms compared to their primary host or surrounding tissues. " 04/01/2001 - "Phosphocreatine in control (saline treated) tumors showed a significant decrease only at 24 hours (p < 0.01). " 06/01/1997 - "The latter shared high proportions of phosphocreatine, phosphocreatine > 30% of total phosphate, indicating substantial amounts of muscle tissue included in the tumor voxels (partial volume effect). " 02/01/1997 - "Therefore, the use of the phosphocreatine shuttle as a process mandatory for the active growth of some cancer cells is questioned."

Related Drugs and Biologics

1.	Adenosine Triphosphate (ATP)
2.	Creatine
3.	Lactic Acid
4.	Phosphocreatine (Neoton)
5.	Glycogen
6.	triphosphoric acid (triphosphate)
7.	Phosphotransferases (Kinase)
8.	N-acetylaspartate (N-acetyl aspartate)
9.	Choline (Choline Chloride)
10.	Adenine

Related Therapies and Procedures

1.	Ischemic Postconditioning
2.	Induced Heart Arrest (Cardioplegia)
3.	Cardiopulmonary Bypass (Heart-Lung Bypass)
4.	Microspheres (Microsphere)
5.	Heterologous Transplantation (Xenotransplantation)